Paper Review Records
All Paper Review Records
16 valid samples · Newest publication first
Review days = acceptance date − received date. PDF, DOI, and publisher-page sources are retained.
Patient preferences and travel burden before radiotherapy for primary cutaneous lymphoma: baseline results from the S-MISR registry
David Rene Steike; Khaled Elsayad; Isabel Falke; Christian Kandler; Hans Theodor EichShow moreShow less
1. Department of Radiation Therapy – Radiation Oncology, University Hospital of Münster, Münster, Germany; 2. Department of Radiation Oncology, Marburg Ion-Beam Therapy Center (MIT), UKGM Marburg, Marburg, Germany; 3. Department of Radiation Oncology, UKGM Marburg, Marburg, Germany; 4. University Cancer Center (UCT) Frankfurt-Marburg, Marburg, Frankfurt, Germany; 5. Department of Radiooncology, Clemenshospital Muenster, Münster, Germany; 6. Radiox Hamm, Hamm, GermanyShow moreShow less
Comparative toxicity and efficacy of consolidative thoracic radiotherapy after first-line chemoimmunotherapy in extensive-stage small-cell lung cancer: real-world retrospective cohort study
Bing Bai; Yuhua Jiang; Hanqing Meng; Lei Song; Kai Wu; Jun Wei; Na SiShow moreShow less
1. Department of Oncology, Yiyuan County People’s Hospital, Zibo, China; 2. Department of Thoracic Surgery, Yiyuan County People’s Hospital, Zibo, China; 3. Department of Medical Imaging, Yiyuan County People’s Hospital, Zibo, ChinaShow moreShow less
Evaluation of PET-detected nodal upstaging and planning target volume expansion in esophageal cancer radiotherapy planning
Sanyamita Jain; Brijesh Maheshwari; Akash R. Bellige; Sarthak Tandon; Apoorva Nayak; Abhishek Bhadri; Sachin Pandey; Parveen Ahlawat; Munish GairolaShow moreShow less
1. Department of Radiation Oncology, Rajiv Gandhi Cancer Institute and Research Centre, New Delhi, IndiaShow moreShow less
Author’s reply to Rao et al.—“DEGRO practical guidelines: radiotherapy of breast cancer-regional nodal irradiation”
Kai Borm; Marciana Nona Duma; David Krug; Juliane Hörner-RieberShow moreShow less
1. Department of Radiation Oncology, TUM School of Medicine and Health, Technical University of Munich (TUM), Klinikum rechts der Isar, Munich, Germany; 2. Department of Radiation Oncology, Helios Clinics of Schwerin, University Campus of MSH Medical School Hamburg, Schwerin, Germany; 3. Department for Human Medicine, MSH Medical School Hamburg, Hamburg, Germany; 4. Department of Radiotherapy and Radiation Oncology, University Hospital Schleswig-Holstein, Christian Albrechts University Kiel, Kiel, Germany; 5. Department of Radiation Oncology, University Hospital Düsseldorf, Düsseldorf, GermanyShow moreShow less
Increased number of chemotherapy cycles during radiochemotherapy improves overall survival without increasing toxicity in locally advanced non-small cell lung cancer patients
Anna Simbirova; Steffen Löck; Steffen Appold; Alex Zwanenburg; Dirk Koschel; Olaf Holotiuk; Rebecca Bütof; Esther G. C. TroostShow moreShow less
1. OncoRay—National Center for Radiation Research in Oncology, Faculty of Medicine and University Hospital Carl Gustav Carus, TUD Dresden University of Technology, Helmholtz-Zentrum Dresden-Rossendorf, Dresden, Germany; 2. Department of Radiotherapy and Radiation Oncology, Faculty of Medicine and University Hospital Carl Gustav Carus, TUD Dresden University of Technology, Dresden, Germany; 3. National Center for Tumor Diseases (NCT), NCT/UCC Dresden, a partnership between DKFZ, Faculty of Medicine and University Hospital Carl Gustav Carus, TUD Dresden University of Technology, and Helmholtz-Zentrum Dresden-Rossendorf (HZDR), Dresden, Germany; 4. Department of Internal Medicine and Pneumology, Fachkrankenhaus Coswig, Coswig, Germany; 5. Medical Department I, Division of Pneumology, University Hospital Carl Gustav Carus, TU Dresden, Dresden, Germany; 6. Gemeinschaftspraxis Pathologie, Dresden, Germany; 7. Helmholtz-Zentrum Dresden-Rossendorf, Institute of Radiooncology—OncoRay, Dresden, Germany; 8. German Cancer Consortium (DKTK), Partner Site Dresden, and German Cancer Research Center (DKFZ), Heidelberg, GermanyShow moreShow less
Prä- versus postoperative stereotaktische Radiotherapie von Hirnmetastasen
Paul Jan Warnke; Eirini Moysolgou; Olaf WittensteinShow moreShow less
1. Institute of Anatomy, Faculty of Medicine and University Hospital Carl Gustav Carus, TUD Dresden University of Technology, Dresden, Deutschland; 2. Klinik für Strahlentherapie, UKSH Campus Kiel, Kiel, DeutschlandShow moreShow less
FAQ
How long does STRAHLENTHERAPIE UND ONKOLOGIE take to review a manuscript?
As of 2026-11-19, CrushSCI has 16 complete review records for STRAHLENTHERAPIE UND ONKOLOGIE. The fastest paper went from submission to acceptance in 3 days (Dauer der Androgendeprivationstherapie bei der Radiotherapie des lokalisierten Prostatakarzinoms – braucht es wirklich 36 Monate?, received 2026-05-18, accepted 2026-05-21); the slowest took 271 days. The average is 66.8 days and the median is 59 days. The fastest record has an unusually short interval; please check the original source.
Expert Matching · Case Demo
Turn Your Submission Goalsinto a Verifiable Journal Plan
Share your field, deadline, and author profile. CrushSCI uses real review records to suggest a title direction, shortlist journals, and estimate timelines.
